 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Cindy O'Bryant and Melanie Joy.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.777 |
|
|
|
-
Thompson LE, Ghimire A, Wen X, Kim C, Doherty CL, Buckley BT, Bowles DW, O'Bryant CL, Jaimes EA, Aleksunes LM, Joy MS. Population Pharmacokinetic Model of Platinum Disposition in Cancer Patients Receiving Cisplatin and Randomized to 5-HT3 Antagonist Antiemetic Drugs. J Clin Pharmacol. 2025 Jun; 65(6):763-778.
Score: 0.241
-
Thompson LE, Ghimire A, Wen X, Kim C, Choza J, Doherty CL, Buckley BT, Bowles DW, O'Bryant CL, Pfister DG, Jaimes EA, Aleksunes LM, Joy MS. A Pharmacokinetic/Toxicodynamic Model of Cisplatin Nephrotoxicity Using the Kidney Injury Molecule-1 Biomarker. J Pharmacol Clin Toxicol. 2024; 12(1).
Score: 0.237
-
Ibrahim ME, Chang C, Hu Y, Hogan SL, Mercke N, Gomez M, O'Bryant CL, Bowles DW, George B, Wen X, Buckley B, Aleksunes L, Joy MS. Pharmacokinetic determinants of cisplatin-induced subclinical kidney injury in oncology patients. Eur J Clin Pharmacol. 2019 Jan; 75(1):51-57.
Score: 0.156
-
Chang C, Hu Y, Hogan SL, Mercke N, Gomez M, O'Bryant C, Bowles DW, George B, Wen X, Aleksunes LM, Joy MS. Pharmacogenomic Variants May Influence the Urinary Excretion of Novel Kidney Injury Biomarkers in Patients Receiving Cisplatin. Int J Mol Sci. 2017 Jun 22; 18(7).
Score: 0.143
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|